BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30782821)

  • 1. Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities.
    Terakawa J; Serna VA; Taketo MM; Daikoku T; Suarez AA; Kurita T
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4528-4537. PubMed ID: 30782821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiles of benign and (pre)malignant endometrial lesions.
    van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
    Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.
    Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH
    Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
    Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
    Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
    Xiong Y; Xiong YY; Zhou YF
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.
    Joshi A; Miller C; Baker SJ; Ellenson LH
    Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma.
    Chibbar R; Foerstner S; Suresh J; Chibbar R; Piche A; Kundapur D; Kanthan R; Kundapur V; Lee CH; Agrawal A; Lai R
    Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):181-188. PubMed ID: 36695555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
    Strickland AL; Rivera G; Lucas E; John G; Cuevas I; Castrillon DH
    Int J Gynecol Pathol; 2019 Nov; 38(6):503-513. PubMed ID: 30256235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression.
    van der Zee M; Jia Y; Wang Y; Heijmans-Antonissen C; Ewing PC; Franken P; DeMayo FJ; Lydon JP; Burger CW; Fodde R; Blok LJ
    J Pathol; 2013 May; 230(1):48-58. PubMed ID: 23288720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
    Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
    Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
    Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
    Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
    Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
    Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
    J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.
    Richards JS; Fan HY; Liu Z; Tsoi M; Laguë MN; Boyer A; Boerboom D
    Oncogene; 2012 Mar; 31(12):1504-20. PubMed ID: 21860425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of Leydig cells and stromal hyperplasia in the postmenopausal ovary of women with endometrial carcinoma.
    Reijnen C; Küsters-Vandevelde HVN; Abbink K; Zusterzeel PLM; van Herwaarden AE; van der Laak JAWM; Massuger LFAG; Snijders MPLM; Pijnenborg JMA; Bulten J
    Hum Pathol; 2019 Mar; 85():119-127. PubMed ID: 30428390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.